MedPath

Drug effects on blood pressure, heart rate, and eyes in children with refractive error

Phase 3
Completed
Conditions
Refractive error
Eye Diseases
Disorder of refraction, unspecified
Registration Number
ISRCTN17363525
Lead Sponsor
Research Unit of Cicendo National Eye Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
54
Inclusion Criteria

Children 6-18 years of age who had mild to moderate refractive errors before administration of cycloplegic agents (myopia <6.00 D, hyperopia <3.00 D, and astigmatism <3.00 D)

Exclusion Criteria

1. Visual disturbances unrelated to refractive errors, such as corneal opacities, uveitis, glaucoma, cataracts, posterior segment disorders, and disorders of the optic nerve/visual pathway
2. History of ocular surgery
3. Pupillary abnormalities or other neurological disorders
4. History of cardiovascular disease
5. Receiving systemic or ocular medical therapy that affects pupil function and/or accommodation
6. High anisometropia (difference in eye refractive status =2.00 D)
7. Strabismus, amblyopia
8. Light colored iris (green or blue iris)
9. Albinism
10. History of allergy to the components of the research drug
11. Children who were not cooperative during drug administration, did not complete autorefractometer and pupil diameter measurements, or developed adverse drug reactions after administration of the regimen

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Refractive power measured using autorefractometry and IOLMaster®700 examination in both eyes at 60 minutes after administration of the first drops of the combination drug regimen.
Secondary Outcome Measures
NameTimeMethod
Blood pressure and heart rate measured using Omron Automatic Blood Pressure HEM 7120 at 60 minutes after administration of the first drops of a combination drug regimen
© Copyright 2025. All Rights Reserved by MedPath